 Home > Active Ingredient News > Drugs Articles > Analysis of the stock price and market value of 14 Chinese pharmaceutical companies affected by the pre-delisting in the United States

Analysis of the stock price and market value of 14 Chinese pharmaceutical companies affected by the pre-delisting in the United States

 Last Update: 2022-08-10
 Source: Internet
 Author: User

Tags

jp 5 0

analgesic drugs list

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In the past three months from March 8, 2022 to the present, the " Foreign Company Accountability Act " and related " pre-delisting list " and " determined delisting list " introduced by the United States have attracted great attention from China and the wor.

The Foreign Company Accountability Law Pre-Delisting List Confirms the Delisting List

Among them, 14 Chinese pharmaceutical companies were affect.

The first batch of 14 Chinese pharmaceutical companies : BeiGene, Zai Lab, and Chi-Med Pharmaceutical.

The age of medicine

A total of 128 companies in six batches were included in the pre-delisting list of the "Foreign Company Accountability Law", including 14 pharmaceutical companies including BeiGene, Zai Lab, Hutchison, Legend, Tianjing, and Kexing

Alert! The latest "Foreign Company Accountability Law" pre-delisting list announced, no Chinese pharmaceutical companies / biotechnology companies

Now, based on the collected data, we conduct a quick and simple analysis of these 14 companies from the perspective of stock price and company market val.

We firmly believe that as long as we persist in innovation and do the right thing, Chinese pharmaceutical/biotech companies will surely be able to get out of the trough and their value will surely be recognize.

We firmly believe that as long as we persist in innovation and do the right thing, Chinese pharmaceutical/biotech companies will definitely be able to get out of the trough, and their value will definitely be recognized

0 The company's total market value decline list

The company's total market value decline ranking

BeiGene is currently listed on the Nasdaq, the Hong Kong Stock Exchange and the Science and Technology Innovation Boa.

Year-to-date, the top ten companies with the lowest total market capitalization decline are:

Top 10 companies with the lowest decline in total market capitalization

(1) Kexing Bio (0%) (2) Legend Bio (-32%) (3) BeiGene (Science and Technology Innovation Board, -45%) (4) 1 Yaowang (-414%) (5) Genuine Hi Bio (-485%) (6) BeiGene (NASDAQ, -556%) (7) BeiGene (HKEx, -537%) (8) Zai Lab (NASDAQ, -543%) (9) Zai Lab (HKEx, -547%) (10) Kaixin Yuanda Pharmaceutical (-575%)

In addition to the special situation of Sinovac due to the suspension of trading, legendary creatures suffered the smallest decline, only -3

Year-to-date, the top ten companies with the highest decline in total market value are:

Top 10 companies with the highest decline in total market value

(1) Conrad Bio (-85%) (2) Tianjing Bio (-855%) (3) Genetron Health (-723%) (4) Burning Rock Medicine (-703%) (5) He Huang Medicine (Hong Kong) Stock Exchange, -795%) (6) Hutchison Pharmaceuticals (NASDAQ, -775%) (7) Wanchun Pharmaceutical (-786%) (8) Tianyan Pharmaceutical (-63%) (9) Kaixin Yuanda Pharmaceutical (-575%) (10) Zai Lab (HKEx, -547%)

0 Enterprises with market value of 100 million yuan, 10 billion yuan, and 100 billion yuan

Enterprises with market value of 100 million yuan, 10 billion yuan, and 100 billion yuan

From the perspective of the company's market value, let's analyze the market value distributi.

At present, only BeiGene (Science and Technology Innovation Board) and BeiGene (Hong Kong Stock Exchange) have a market value exceeding the 100 billion mark, with 11623 billion yuan and 10545 billion Hong Kong dollars respective.

At present, the market value exceeds the 10 billion mark: Zai Lab (Hong Kong Stock Exchange), BeiGene (NASDAQ), Chi-Med Pharmaceutical (Hong Kong Stock Exchange), respectively: 2186 billion Hong Kong dollars, 1944 billion US dollars, 1262 billion billion Hong Kong dolla.

The market value of Legend Bio is 59 billion US dollars, when will it break the 10 billion US dollar mark? Worth watchi.

The list of companies that fell below the 100 million yuan mark is: Connecticut Bio ($48 million); Kaixin Yuanda Pharmaceutical ($53 million); Wanchun Pharmaceutical ($54 millio.

Companies close to the 100 million yuan mark are: Tianyan Pharmaceutical ($123 million); Genetron Health ($131 million); 1 Drug Network ($160 million)

0 The stock price is over 100 yuan and less than 1 yuan

Share price over 100 yuan, less than 1 yuan

From the perspective of the company's stock price, let's analyze the distributi.

At present, the only company with more than 100 yuan is BeiGe.

Next is BeiGene Science and Technology Innovation Board, with a stock price of 854 yuan; BeiGene Hong Kong Stock Exchange, with a stock price of 73 Hong Kong dollars; Legend Bio at 473 dollars; Zai Lab Nasdaq with 29 dollars; Zai Lab Hong Kong Stock Exchange with 205 Hong Kong dollars ; Chi-Med Hong Kong Stock Exchange 134 yuan; Chi-Med NASDAQ $5

The current share price is lower than one yuan: Connected Biotech $5573; Kaixin Yuanda Pharmaceutical $310 Those close to the one-yuan threshold are: Wanchun Pharmaceuticals $13; Genetron Health 25; 1 Drug Network $3

See the table below for detai.

0 Ride the wind and waves, forge ahead!

Ride the wind and waves, forge ahead!

As the radar of China's pharmaceutical industry, Pharmaceutical Times has been scanning the daily industry tren.

The age of medicine

We report both the good news that comes frequently and the unfortunate bad ne.

There is only one goal, that is: to help the heroes who are committed to the research and development of new drugs to see the way forward, to constantly adjust, and to move forward bett.

Ultimately develop more and better new drugs!

The era of medicine pays tribute to the heroes of new drug research and development!

Looking forward to that day coming soon!

Keep working hard together! come on!

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.